Strongest Quarter Hides Moderation Ahead — Guidance Flat Says It All
Marico delivered 27.1% profit growth, the strongest in 28 quarters, but reaffirmed FY27 guidance rather than raising it. The call reveals why: Q1 was commodity-fueled, Q2 headwinds are real, and India volume growth is moderating. The market has priced that in.
₹652 Cr
+27.1% YoY
₹3,957 Cr
+21.4% YoY
20.7%
+40 bps YoY
16.3%
highest in recent quarters
On paper, Q1 FY-2027 is Marico's rarest quarter in a long time — 27.1% profit growth, the highest in 28 quarters, delivered on clean topline momentum and margin expansion. Yet management reaffirmed its full-year guidance rather than raising it, and the stock fell 2.63% on day 1, fading further to −1.49% by day 3. That disconnect is the story: this quarter was an exceptional aberration, not a template. The call explained it frankly; the market has accepted the warning.
Where the profit came from
The 27.1% PAT growth traces to three drivers. First, gross margin expanded 30 basis points year-over-year, driven by copra price deflation — a commodity tailwind, not an operational improvement. Second, Parachute Rigids delivered 10% volume growth, the strongest in 20 quarters, combined with higher pricing from the prior year's 60% input cost hike. Third, portfolio mix shifted premium (VAHO high-teen volume growth, Foods 43% revenue including acquisitions, Digital ARR rising to ₹1,100 Cr+). The compounding effect was a 27.1% profit beat. But management was clear: of these three, only the second — brand execution — is sustainable.
Crude and vegetable oils continue to exhibit an upward bias. And consequently, we expect input costs to be relatively higher in Q2.
Copra, which accounted for much of Q1's tailwind, is now range-bound 30-35% below its peak. Meanwhile, crude and vegetable oils — which feed polymers, LP, and cost of goods broadly — are up 60-70%. Management signaled Q2 will see margin pressure; EBITDA margin expansion will require mix shift and fixed-cost absorption, not price-driven leverage. This is not a problem if brand momentum holds, but it's a shift from Q1's setup.
What changed on this call
Consolidated revenue growth of 23%
Delivered 21.4% YoY; opening remark overstated by ~1.6 pp
Overstated
EBITDA and PAT growth of 25%
PAT grew 27.1% YoY; call under-guided profit, accurate on margin run-rate (20.7%)
Conservative on PAT
Parachute 10% volume sustainable
Called 'an aberration'; expect mid-single digit FY27
Overstated
FY27 guidance: ₹15,000 Cr+ revenue, high-teen EBITDA growth
Reaffirmed, not raised; added 'aspiration' for 20% EBITDA growth (not commitment)
Maintained, cautious tone
India volume +11%, international +15% CC
Confirmed; but FY27 guidance reset to high single-digit India volume, mid-teens international (vs prior high-teen ambition)
Supported but forward guidance moderating
The largest change vs. prior calls is India volume guidance. Parachute's 10% volume, driven by supply-chain efficiency (thin pipeline, AI-led demand sensing) and pricing discipline after the prior year's hikes, was explicitly called 'an aberration'. Management now guides high single-digit volume growth for India business in FY27, and mid-single digit for Parachute specifically. Saffola, meanwhile, is declining high single-digit (down from mid-single-digit growth in prior years) as management strategically exits low-margin packs in favor of premium cold-pressed oils. This is profitability-driven, not demand-driven — a tactical retreat.
International, too, is signaling moderation. Bangladesh grew only 4% (inflation, demand softness, pricing anniversarization), despite management's prior emphasis on international mid-teen growth as a pillar. Vietnam is strong (27%), MENA at 24%, but overall international guidance remains mid-teens, not upgraded. The FY27 roadmap is: hold the ₹15,000 Cr target, defend margins via mix, accept volume moderation, and hope new ventures (₹100 Cr Almond by FY28, ₹100 Cr Shampoo Year 1) backfill the core growth shortfall.
The bull-bear ledger
Parachute's 10% volume and market share gains in coconut oil — rare in 20 years
Premium mix shift real: VAHO high-teen growth, Foods/Premium PC scale-up, Digital ₹1,100 Cr ARR
Supply-chain advantage (Project SETU, AI-led demand sensing) creating pricing power vs. peers
Disciplined capital allocation: Digital brands at 20-25% growth (vs 40-50%+ burn elsewhere), Beardo profitable at ₹200+ Cr ARR
Q1 profit growth (27.1%) commodity-fueled, not operational — copra deflation the main driver
Q2+ headwinds explicit: crude/veg oils +60-70%, margin pressure flagged, guidance reaffirmed not raised
India volume moderation: Parachute mid-single digit FY27, Saffola down, overall India high single-digit — growth slowing
International slowdown: Bangladesh 4%, MENA inflationary; mid-teens guidance suggests no upside vs prior
New ventures ambitious but unproven at scale: Almond disruptive if market share captured, but ₹100 Cr by FY28 is aggressive; Shampoo enters crowded multinational-dominated category
Digital profitability path unproven: Plix high single-digit margin at ₹800+ Cr ARR, Cosmix high-teens but burn on others continues
Risks, ranked by holder concern
Q2+ commodity headwinds: crude/veg oils +60-70%, margin pressure likely
HighManagement targeting 140-150 bps EBITDA margin expansion to hold high-teens growth at ₹15K Cr revenue. Gross margin defense via pricing is limited (Saffola volume decline shows pricing elasticity); mix shift carries execution risk. If Q2 margins compress more than modeled, FY27 EBITDA guidance risk.
India volume moderation: high single-digit guidance vs prior double-digit ambition
HighParachute 10% is 'aberration,' not repeatable. Guidance reset to mid-single digit + Saffola down = India business growth ceiling lowered. If macro weakens further (consumer slowdown, inflation), even high single-digit volumes at risk. ₹15K Cr revenue target increasingly dependent on international + new ventures.
International slowdown: Bangladesh 4%, geopolitical risks in Gulf
Medium-HighBangladesh is 20%+ of international revenue; 4% growth is material decel from prior double-digit. MENA facing inflation/fuel cost pressures despite 24% reported growth. Guidance mid-teens (vs 15% Q1 actual) suggests no upside expectation. If Bangladesh deteriorates further, international drag on group growth.
New venture execution: Almond ₹100 Cr by FY28, Shampoo ₹100 Cr Year 1, Cold-pressed oils
MediumAmbitious but unproven at India scale. Almond market leader has 70%+ share; Marico must disrupt. Shampoo enters crowded category dominated by multinationals. If execution stumbles (market share not captured, pricing eroded), portfolio diversification target at risk, and FY28 guidance reset likely.
Digital profitability stalled at scale: Plix high single-digit at ₹800+ Cr, Cosmix profitable but others burning
MediumVision 2030 targets ₹4K Cr digital EBITDA margin by 2030. Path to profitability is 12-18 months per management; Plix margin trajectory (high single-digit) suggests low double-digit at ₹1K Cr scale, not the 15-20% the group needs for ₹4K Cr EBITDA CAGR. Competitive intensity (Tata One, private labels) pressuring CAC and unit economics.
How the market is positioned
The stock fell 2.63% on day 1 post-result (announced at ₹875 pre-result close), with the decline extending to −1.49% by day 3. As of 2026-08-11, it trades at ₹855, down 3.8% from its all-time high, yet +21.14% off its 52-week low. The tape is telling: the market saw the 27.1% profit print and the strong Q1 execution, but parsed management's caution (flat guidance, Q2 headwinds, volume moderation) as a peak-quarter story. RSI at 46.9 (neutral) and normal volume confirm a digestion, not a route.
Ownership tells a similar story. FII holdings dropped 68 basis points quarter-over-quarter (from 24.08% to 23.40%), while DII added 72 bps. This is not panic, but selective exit — large foreign funds trimming exposure to a stock that just hit cycle highs on earnings, ahead of flagged headwinds. Promoter holding steady at 59.02%. The domestic setup (DII accumulation vs FII trim) suggests Indian institutions see value at the dip, but foreigners are raising caution.
The debate
The honest read: Marico is a fundamentally sound franchise. The 27.1% profit growth this quarter is real and driven by solid brand execution (Parachute, VAHO) plus favorable commodity timing. But it is not repeatable. Management's decision to reaffirm guidance rather than raise it, combined with explicit flagging of Q2 headwinds and India volume moderation, signals a strong start to FY27, not a new growth trajectory. The market's day-1 selling was justified. At ₹855, the stock offers fair value for a patient buyer betting on portfolio diversification (Foods, Premium PC, Digital) and new venture execution, but not a compelling entry for momentum buyers. The FY27 roadmap is: hold the ₹15K Cr target, defend margins, moderate volume growth, and prove new ventures work. Execution on that plan, not the Q1 beat, is the real test ahead.
What to watch next
1 · Q2 gross margin defense
Management expects crude/veg oil headwinds in Q2. Watch whether gross margin holds steady (>20.6%) or compresses 20-50 bps. Compression confirms commodity cycle dependency; flat margins confirm pricing power and mix leverage. This is the baseline test of the underlying franchise.
2 · Parachute and Saffola volume trajectory in H2 FY27
Parachute guidance is mid-single digit for the full year (implying moderation post-Q1's 10%). Saffola is guiding high single-digit down. Watch whether these volumes stabilize at those levels (manageable) or accelerate downward (warning of macro weakness or pricing limits). This determines whether ₹15K Cr target stays on track.
3 · New venture Q1-Q2 traction: Shampoo and Almond launch
Parachute Advanced shampoo is targeting ₹100 Cr Year 1. Almond oil is targeting ₹100 Cr by FY28. Both are in early stages. Watch distribution ramp, pricing feedback, and market share capture. Early wins (Shampoo at ₹15-20 Cr+ in Q2, Almond at ₹5-10 Cr+ by Q3) would boost confidence in portfolio diversification; stumbles would signal execution risk and likely compression of FY28 upside.
Marico delivered a rare quarter — 27.1% profit growth, execution on Parachute, margins stable — but it was an aberration, not a template. The stock is fairly valued at ₹855, and the investment case turns on three things: margin defense in Q2 despite commodity headwinds, India volume stabilization at guided high single-digit, and new venture execution (Shampoo, Almond) backfilling core growth slowdown. Holders should be patient; new buyers should wait for clarity on Q2. The number to track from here is not the headline profit, but the organic volume growth and margin rate in the next two quarters — those will tell whether Marico is entering a softer phase or defending the premium franchise.
Marico Q1 FY27: Consol PAT +25% YoY to ₹630 Cr as revenue beats guidance, margins steady
PAT +25% YoY · revenue +22.85% · margins expanding · beat vs street
₹3,957 Cr
+22.85% YoY
₹630 Cr
+25% YoY
15.73%
+0.3pp YoY
₹4.86
Marico's consolidated revenue came in at ₹3,957 Cr for Q1 FY27, up 22.9% YoY and 19.9% QoQ, with PAT attributable to owners at ₹630 Cr, up 25.0% YoY (group net profit ₹652 Cr including ₹22 Cr non-controlling interests). Basic EPS rose to ₹4.86 from ₹3.90 a year ago. Standalone told a very different story: revenue grew a similar 18.9% YoY to ₹2,794 Cr, but standalone PAT fell 55.5% YoY to ₹344 Cr — entirely because standalone other income (largely dividends up-streamed from subsidiaries) dropped to ₹53 Cr from ₹473 Cr a year ago. That's a timing effect specific to the parent-only books and is eliminated on consolidation, so it should not be read as a sign of operating weakness; the consolidated print is the one that reflects underlying performance.
Q1 FY-2027 vs prior quarters
Net profit margin expanded to 16.5% from 15.9% a year ago, and the sequential jump from 12.4% in Q4 FY26 is partly the usual Q4-to-Q1 seasonal pattern in FMCG (Q4 typically carries heavier trade/inventory adjustments) rather than a step-change, so it shouldn't headline over the YoY move. By segment, India revenue grew 20.9% YoY to ₹3,003 Cr with segment PBIT up 23.7% to ₹580 Cr, while International grew faster at 29.3% YoY to ₹954 Cr with PBIT up 20.7% to ₹257 Cr — the international number is partly boosted by the consolidation of Vietnam's Skinetiq (Candid skincare brand, 75% stake acquired effective April 2, 2026), which the company itself flags as not comparable to prior periods.
The stock went into the print at ₹875, up 4.4% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
What the summary numbers don't show
NPM expanded to 16.5% from 15.9% YoY — consolidated PBT margin ~20%, broadly flat as copra cost tailwinds offset A&P/opex investment
Beardo (Zed Lifestyle) business vested into the standalone entity effective June 29, 2026, restating standalone comparatives; Just Herbs integration (Oct 1, 2025) also reflected
Revenue restated across all periods (customer A&P now netted against revenue rather than expensed) — PBT, PAT and EPS unaffected by the reclassification
Management guides for a strong FY27, targeting double-digit consolidated revenue growth to over INR 15,000 crores and high-teen EBITDA growth, subject to stable macros. This is expected to be driven by sustained high single-digit volume growth in the India business and mid-teen constant currency growth in the internati
— This quarter: beat
The quarter runs ahead of both external and company guidance. Marico had pre-announced on July 2 that it expected consolidated revenue growth 'in the early twenties' for the quarter, and Nomura had modelled roughly 18.5% YoY — the actual 22.9% beats both. Against the broader FY27 outlook set out on the Q4 FY26 call (double-digit consolidated revenue growth toward over ₹15,000 Cr and high-teen EBITDA growth), this quarter's revenue growth and roughly 25% growth in PBT+depreciation-based EBITDA run comfortably ahead of the low end, though it is only one of four quarters against a full-year target. No separate management press release or commentary was included in this filing beyond the board outcome letter and financial statements/notes, so India volume growth and international constant-currency growth — both watch items flagged pre-result — cannot be independently verified from this document; the July 2 business update had separately indicated India volumes at a 'multi-quarter high' and copra prices down roughly 45% from peak, aiding gross margin.
W1
Margin durability if copra prices rebound from their ~45% correction off peak — current OPM/NPM expansion rests partly on this input-cost tailwind
W2
Normalization of standalone other income (dividends from subsidiaries) after Q1's unusually low ₹53 Cr vs ₹473 Cr a year ago
W3
International segment's organic growth rate once the Skinetiq (Vietnam) consolidation, included from April 2, 2026, anniversarizes
Consolidated PAT of ₹630 Cr is owners' share (EPS is computed on this base); group net profit before non-controlling interests was ₹652 Cr (PBT ₹790 Cr − tax ₹138 Cr), with NCI ₹22 Cr — this reconciles the PBT-tax check. Standalone other income swung from ₹473 Cr (Q1 FY26) to ₹53 Cr (Q1 FY27), driving a standalone PAT decline that is a dividend-timing artifact, not an operating trend; consolidated eliminates it. Revenue restated across all comparatives (customer A&P now netted off revenue instead of shown as expense) — no P&L/EPS impact. Skinetiq (Vietnam) consolidated from Apr 2, 2026 and Beardo vested into the standalone entity from Jun 29, 2026 (restating standalone comparatives) — both flagged by the company as non-comparability items. The pre-result preview's numeric revenue-range field (~₹350–370 Cr) appears to be a data error given actual scale; used its 'early-20s growth' narrative guidance instead.
Volume Momentum & Margin Tailwinds Enter a High-Valuation Test
Marico guides early-20s revenue growth for Q1 FY27 on multi-quarter volume highs and easing input costs. The Street watches whether the company can defend margins and growth at 52–61x forward earnings as copra prices rebound risk.
The Setup: Volume Inflection Amid Cost Ease
Marico enters Q1 FY27 on its strongest volume footing in several quarters. On 2 July, management telegraphed consolidated revenue growth in the early 20s (20–29%), driven by double-digit underlying volume growth in India oils, mid-teens constant currency growth in international markets (Vietnam, MENA leading), and a new-product tailwind from the May launch of Parachute Advansed Protein Shampoo—the company's entry into haircare. Gross margin is expected to improve sequentially: copra prices have corrected 45% from peak, and management anticipates strong operating profit growth from both business momentum and input-cost relief. This is the narrative the Street will test on 4 August.
~₹350–370 Cr
Early-20s growth v/s prior-year Q1; India + international + new product
~16–17%
Sequential recovery from Q4 FY26 as copra prices ease; 150–200 bps target
~12–15%
Multi-quarter high in Parachute Coconut Oil; premium portfolio ASP boost
~14–18%
Vietnam, MENA strength; contributions from other markets
A strong Q1 print would show: volume growth in double digits across India oils (especially Parachute), robust international growth sustained in const-currency terms, gross margin expansion of 150+ bps y/y despite modest input-cost inflation, and profit growth outpacing revenue growth as operational leverage kicks in. Haircare entry (Parachute Advansed Shampoo) would show early traction in revenue contribution (though not material to Q1 number). A weak print would indicate: volume growth slower than 10%, or significant price/mix deterioration in oils, margin expansion falling short of 100 bps due to residual input pressures, or international markets losing momentum. Management guidance at the call will be watched closely for full-year margin and growth assumptions.
Is the Company Tracking Guidance?
Marico's FY26 full-year performance (announced May 2026) and 2 July business update suggest the company is on track for its full-year guidance, but with caveats. FY26 saw headline revenue growth constrained by volume headwinds in legacy oils and elevated copra costs that pressured margins; management signaled that Q1 FY27 would mark an inflection as volumes recover and input costs ease. The 2 July update confirmed this trajectory: volumes are accelerating (India oils at multi-quarter high), and copra prices have fallen sharply. However, the stock's rally from ₹775 (52w low) to ₹871 (current) reflects market euphoria on both growth and valuation expansion. The Street's debate centers on whether this growth is sustainable and whether the company's current 52–61x forward P/E multiple is justified by the pace of earnings recovery.
What the Street Says
1 · Haircare Platform Launch (May 26)
Marico entered the hair-cleansing category with Parachute Advansed Protein Shampoo, extending the Advansed brand from hair oil into shampoo. This is operationally significant—a new growth avenue beyond oils and foods. Q1 contribution will be small, but Street will probe management for penetration, ASP, and go-to-market plans. Risk: if hair-cleansing fails to gain scale, it weakens the growth narrative.
2 · Zed Lifestyle Restructuring (June 29)
Marico completed an intra-group restructuring of Zed Lifestyle (wholly-owned subsidiary, distributes premium home- and personal-care products). This was a tax-efficient and organizational tidying, not a strategic pivot or exit. Routine for a diversified FMCG house; no impact on Q1 numbers, but shows management focus on group optimization.
3 · Dividend & AGM (July 9, Aug 6)
Board approved a final ₹4.00 per-share dividend for FY26 (record date July 30). AGM scheduled for August 6, 2026 (two days post-result). Independent Director Milind Barve retired effective August 1. These are routine corporate actions but worth noting: no surprise dividend hike or cut; governance transitions proceeding as planned.
4 · Ownership Stability
Latest shareholding (Q4 FY26): promoter 59.04%, FII 24.08%, DII 12.30%. Q-o-Q, FII +7 bps, DII −4 bps, promoter −2 bps. No material pledging or block deals reported. Ownership is stable; no insider trading red flags.
The Watch List for August 4
1 · Gross Margin Expansion & Copra Price Path
The crux. Management guided that copra prices are down 45% from peak and positioned for 150–200 bps operating margin recovery in coming quarters. Q1 will show the first proof of this thesis. Watch the gross margin number closely and management's commentary on near-term copra trends and average realization. If gross margin rises only 80–100 bps y/y despite the 45% copra correction, it signals unexpected headwinds (mix, waste, supply-chain cost pass-throughs). If it exceeds 200 bps, upside surprise.
2 · Volume vs. Price Growth Breakdown (India Oils)
The 2 July update flagged 'double-digit underlying volume growth' in India oils, a multi-quarter high. Q1 results will show the split between volume and price. A print with >12% volume growth in oils (especially Parachute Coconut Oil) validates the capacity/manufacturing recovery post-COVID and competitive position. Slower volume (<10%) or larger-than-expected price contribution would suggest the company is running out of pricing power or facing category softness.
3 · Haircare Traction & Full-Year Guidance
The Parachute Advansed Shampoo launch in May is too recent to show material Q1 contribution, but management should guide on launch momentum, SKU strategy, and go-to-market targets for FY27. Additionally, the Street will press for clarity on full-year consolidated growth outlook, margin guidance, and capital allocation (dividend, buyback, investment in new verticals). Weak guidance or cautious commentary on haircare adoption would temper enthusiasm.
Marico reports Q1 FY27 on August 4 against a backdrop of strong volume momentum, favorable commodity pricing, and a newly launched haircare platform—all positioned to drive mid-20s revenue growth and 150+ bps margin expansion. The company's guidance, delivered on 2 July, set up for a solid quarter; the Street will validate or challenge that thesis on the numbers and management's tone on execution risk and full-year sustainability.
However, valuation is a visible elephant: at 52–61x forward P/E, the stock is pricing in multi-year earnings growth with limited margin for disappointment. A quarter that merely meets expectations could trigger profit-taking if the Street sees margin sustainability or haircare risks. Conversely, Q1 outperformance—volume well north of 12%, margin upside to 200+ bps, or haircare showing early viral adoption—would validate the valuation and likely see the stock re-rate higher.
The debate is not revenue growth (that's credible), but whether Marico's return to accelerating profits justifies a top-quintile multiple in a cyclical FMCG space. The result, the margins, and management's candor on execution will determine whether the bear case (valuation correction) or bull case (durable premium multiple) prevails into the second half of FY27.